(Q35952447)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15547646%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Prevention and treatment of the metabolic syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15547646%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15547646%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

S S Daskalopoulou

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15547646%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

D P Mikhailidis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15547646%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

language of work or name

1 reference

1 November 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15547646%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15547646%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15547646%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15547646%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

589-612

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15547646%20AND%20SRC:MED&resulttype=core&format=json

Banting lecture 1988. Role of insulin resistance in human disease

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Impact of body weight and weight loss on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

A new role for diet in reducing the incidence of cardiovascular disease: evidence from recent studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Dietary fatty acids and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Mediterranean diets and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Carbohydrate-induced hypertriglyceridemia: modifying factors and implications for cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Therapeutic lifestyle change and Adult Treatment Panel III: evidence then and now.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

National cholesterol education program keeps a priority on lifestyle modification to decrease cardiovascular disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Orlistat: its current status as an anti-obesity drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effects of the amount and intensity of exercise on plasma lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Comparison of statins in hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Statin-fibrate combination: therapy for hyperlipidemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Choice of drug treatment for obesity-related hypertension: where is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effect of antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The metabolic and circulatory response to beta-blockade in hypertensive men is correlated to muscle capillary density

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Long term propranolol treatment and changes in body weight after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effects of inhibition of the renin-angiotensin system on the cardiovascular actions of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Oral clonidine premedication decreases energy expenditure in human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Drug Treatment of Hypertension in Patients With Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Uric acid: is it a risk factor for cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Regulation of renal urate excretion: a critical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Statins and renal function in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Uric acid levels and vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Analysis of the relationship between fasting serum uric acid and the insulin sensitivity index in a population-based sample of 380 young healthy Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Metformin and metoprolol CR treatment in non-obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Evaluation of the efficacy and safety of Diamicron in non-insulin-dependent diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The pharmacology of sulfonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effect of ciprofibrate on C-reactive protein and fibrinogen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Value or desirability of hemorheological-hemostatic parameter changes as endpoints in blood lipid-regulating trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Fatty liver--an additional and treatable feature of the insulin resistance syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Lipid-lowering drugs and serum liver enzymes: the effects of body weight and baseline enzyme levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effects of various fibrates on serum alkaline phosphatase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Thiazolidinediones: a new class of antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Thiazolidinediones, dyslipidaemia and insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Role of endothelial dysfunction in insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Prevention of type 1 diabetes: what have we achieved? What should we say and propose next to families?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Antihypertensive medications and weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Adipokines, inflammation, and the endothelium in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effect of Metformin and Sulfonylurea on C-Reactive Protein Level in Well-Controlled Type 2 Diabetics with Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

[Adipocytokins, obesity and development of type 2 diabetes].

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Adiponectin and Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The insulin-sensitizing role of the fat derived hormone adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Ethnic differences in adiponectin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Rise in morning saliva cortisol is associated with abdominal obesity in men: A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Visceral obesity and the role of the somatotropic axis in the development of metabolic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Type 2 diabetes and metabolic syndrome in Filipina-American women : a high-risk nonobese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Fibrates for treatment of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Role of fibrates in reducing coronary risk: a UK Consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Associations between insulin resistance and thrombotic risk factors in high-risk South Asian subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Life Style and Cardiovascular Risk Factors in the Japanese Population-From an Epidemiological Survey on Serum Lipid Levels in Japan 1990. Part 1: Influence of Life Style and Excess Body Weight on HDL-Cholesterol and Other Lipid Parameters in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The insulin resistance syndrome and postprandial lipid intolerance in smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Smoking cessation improves insulin sensitivity in healthy middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effect of exposure to secondhand smoke on markers of inflammation: the ATTICA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Insulin resistance and compensatory hyperinsulinemia: the key player between cigarette smoking and cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Hypertriglyceridemia as a cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Risk factors for coronary heart disease in the Japanese--comparison of the background of patients with acute coronary syndrome in the ASPAC study with data obtained from the general population. Asia-Pacific Collaboration on CHD Risk Factor Intervent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Postprandial lipemia and associated metabolic disturbances in healthy and hyperlipemic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Apolipoprotein E polymorphism and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Québec Cardiovascular Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Low prevalence of the metabolic syndrome in wine drinkers--is it the alcohol beverage or the lifestyle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Alcohol consumption in the severely obese: relationship with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Alcohol consumption, the metabolic syndrome and insulin resistance in 58-year-old clinically healthy men (AIR study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Moderate alcohol consumption, estrogen replacement therapy, and physical activity are associated with increased insulin sensitivity: is abdominal adiposity the mediator?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Lipoprotein (a) in android obesity and NIDDM: a new member in 'the metabolic syndrome'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Lipoprotein (a) and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effects of fibrates on serum metabolic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Association between microalbuminuria and the metabolic syndrome: NHANES III

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The metabolic syndrome and chronic kidney disease in U.S. adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Relation of albumin/creatinine ratio to C-reactive protein and to the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Menopause and ischaemic stroke: basic, clinical and epidemiological considerations. The role of hormone replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The influence of hormonal status and features of the metabolic syndrome on bone density: a population-based study of Swedish women aged 50 to 59 years. The women's health in the Lund area study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Metabolic syndrome and coronary angiographic disease progression: the Women's Angiographic Vitamin & Estrogen trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Sleep disordered breathing--a new component of syndrome x?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Quantification of insulin-mediated glucose disposal in HIV-infected individuals: comparison of patients treated and untreated with protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Gamma-glutamyl transpeptidase and the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Treatment of Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Current best treatment for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Therapeutic Options in Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Novel cardiovascular risk factors and macrovascular and microvascular complications of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Pathophysiological implications of insulin resistance on vascular endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

Insulin resistance, hypertension, and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00033197040550I601

10.1177/00033197040550I601

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15547646%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference